Literature DB >> 2566782

Tin-protoporphyrin and long wave length ultraviolet light in treatment of psoriasis.

L Emtestam1, L Berglund, B Angelin, G S Drummond, A Kappas.   

Abstract

To assess the effects of tin (Sn)-protoporphyrin (a synthetic haem analogue) in conjunction with long wave length ultraviolet light (UVA) radiation in psoriasis 10 patients, 9 of whom were substantially or completely unresponsive to other forms of therapy, received 2.0 mumol/kg bodyweight of Sn-protoporphyrin for 1 day followed by UVA light treatment for 21 days. The average starting UVA dose was 5.6 (SD 2.0) J/cm2, and the average cumulative UVA dose was 98.3 (35.1) J/cm2. Severity of psoriatic plaques, scored clinically on a scale of 0-3 for erythema, scaling, and induration, fell from a mean score of 7.9 at the start of the study to 3.6 at the end. Psoriatic lesions were improved in all patients and the effect was striking in some. The responses lasted throughout the three weeks of the study and no deleterious side-effects of the treatment were noted. Clinical follow-up for three months showed no rebound in disease activity. Sn-protoporphyrin with conventional UVA light may be useful in the treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566782     DOI: 10.1016/s0140-6736(89)92331-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Conditioned pharmacotherapeutic effects: a preliminary study.

Authors:  Robert Ader; Mary Gail Mercurio; James Walton; Deborra James; Michael Davis; Valerie Ojha; Alexa Boer Kimball; David Fiorentino
Journal:  Psychosom Med       Date:  2009-12-22       Impact factor: 4.312

Review 2.  What is a role of haeme oxygenase-1 in psoriasis? Current concepts of pathogenesis.

Authors:  Anna Wojas-Pelc; Janusz Marcinkiewicz
Journal:  Int J Exp Pathol       Date:  2007-04       Impact factor: 1.925

3.  Studies with the haeme oxygenase inhibitor Sn-protoporphyrin in patients with primary biliary cirrhosis and idiopathic haemochromatosis.

Authors:  L Berglund; B Angelin; R Hultcrantz; K Einarsson; L Emtestam; G Drummond; A Kappas
Journal:  Gut       Date:  1990-08       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.